



## [Claims]


35

1. A compound of formula I or formula II



in which



5. A is selected from the group consisting of

one of R<sub>1</sub> and R<sub>2</sub> is selected from H, OH and OCH<sub>3</sub>, and the other of R<sub>1</sub> and R<sub>2</sub> is selected from OH and OCH<sub>3</sub>;one of R<sub>3</sub> and R<sub>4</sub> is selected from H, OH and OCH<sub>3</sub>, and the other of R<sub>3</sub> and R<sub>4</sub> is selected from OH and OCH<sub>3</sub>;provided that at least one of the pairs R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>4</sub> are both OH;R<sub>5</sub> is selected from OH and OCH<sub>3</sub>; and

— denotes a single or double bond;

or a pharmaceutically acceptable salt or prodrug thereof;

15 with the proviso that

(a) when A is or , and R<sub>3</sub> and R<sub>4</sub>are both OH then R<sub>2</sub> is other than H; and(b) when A is and R<sub>3</sub> and R<sub>4</sub> are both OH and R<sub>2</sub> is OCH<sub>3</sub>, then R<sub>1</sub> is other than H or OCH<sub>3</sub>.

20. 2. A compound according to claim 1, wherein

one of R<sub>1</sub> and R<sub>2</sub> is selected from H and OH, and the other of R<sub>1</sub> and R<sub>2</sub> is OH;one of R<sub>3</sub> and R<sub>4</sub> is selected from H and OH, and the other of R<sub>3</sub> and R<sub>4</sub> is OH;


8, 15

provided that at least one of the pairs  $R_1$ ,  $R_2$  and  $R_3$ ,  $R_4$  are both OH;


$R_5$  is OH; and

— denotes a single or double bond.

3. A compound according to claim 1 of the formula (IA) or (IIA)



(IA),



(IIA)

wherein A is as defined in claim 1;


$R_2$  is H, and  $R_1$  is selected from OH and  $OCH_3$ ;

$R_3$  and  $R_4$  are each OH;


$R_5$  is selected from OH and  $OCH_3$ ; and

— denotes a single or double bond.

4. A compound according to claim 1 of the formula (IB) or (IIB)



(IB),



(IIB)

wherein A is as defined in claim 1;

$R_1$  and  $R_2$  are each OH;

$R_3$  is H, and  $R_4$  is selected from OH and  $OCH_3$ ;


$R_5$  is selected from OH and  $OCH_3$ ; and

— denotes a single or double bond.

5. A compound according to claim 1 which is 5-hydroxy-O-demethylangolesin

(5-hydroxy-O-Dma) [1-(2,4,5-trihydroxyphenyl)-2-(4-hydroxyphenyl)-propan-1-one]


having the structure (IV):



(IV)


or a pharmaceutically acceptable salt or prodrug thereof.

6. A compound according to claim 1 which is 3'-hydroxy-O-demethylangolesin (3'-hydroxy-O-Dma) [1-(2,4,4-dihydroxyphenyl)-2-(3,4-dihydroxyphenyl)-propan-1-one] having the structure (V):




5 or a pharmaceutically acceptable salt or prodrug thereof.

7. A compound according to claim 1 which is 3'-hydroxy-O-demethyldehydroangolesin (3'-hydroxydehydro-O-Dma) [1-(2,4-dihydroxyphenyl)-2-(3,4-dihydroxyphenyl)-prop-2-en-1-one] having the structure (VI):




10 or a pharmaceutically acceptable salt or prodrug thereof.

8. A compound according to claim 1 which is 3'-hydroxy-dihydroaidzein having the structure (VII):



or a pharmaceutically acceptable salt or prodrug thereof.

15 9. A compound according to claim 1 which is 1-(2,4,5-trihydroxyphenyl)-2-(4-hydroxyphenyl)-prop-2-en-1-one having the structure (VIII):



or a pharmaceutically acceptable salt or prodrug thereof.



10. A pharmaceutical composition comprising one or more compounds according to claim 1, in association with one or more pharmaceutically acceptable carriers, adjuvants, diluents and/or excipients.

11. A food or drink composition, which contains one or more compounds according to claim 1.

12. A method for the treatment, prophylaxis, amelioration, defence against, and/or prevention of a condition selected from the group consisting of menopausal syndrome; osteoporosis; rheumatic diseases; atherosclerosis; premenstrual syndrome; coronary artery spasm; vascular diseases; Buergers Disease; migraine headaches; hypertension; benign prostatic hypertrophy; cancer; Alzheimers disease; inflammatory diseases; baldness; psoriasis; acne; and diseases associated with oxidant stress; in a patient in need of said treatment, prophylaxis, amelioration, defence against, and/or prevention, which method comprises administering to said patient a therapeutically effective amount of one or more compounds according to claim 1, either alone or in association with one or more pharmaceutically acceptable carriers, diluents, adjuvants and/or excipients.


13. A method for the treatment, prophylaxis, amelioration, defence against, and/or prevention of a hormone-dependent condition in a patient in need of said treatment, prophylaxis, amelioration, defence against, and/or prevention, comprising administering to said patient a therapeutically effective amount of one or more compounds according to claim 1, either alone or in association with one or more pharmaceutically acceptable carriers, diluents, adjuvants and/or excipients.

14. A method for the treatment, prophylaxis, amelioration, defence against, and/or prevention of a hormone-dependent condition in a patient in need of said treatment, prophylaxis, amelioration, defence against, and/or prevention, comprising administering to said patient a therapeutically effective amount of one or more compounds of formula I or formula II



in which

$\wedge$  is selected from the group consisting of



, and

one of  $R_1$  and  $R_2$  is selected from H, OH and  $OCH_3$ , and the other of  $R_1$  and  $R_2$  is selected from OH and  $OCH_3$ ;

one of  $R_3$  and  $R_4$  is selected from H, OH and  $OCH_3$ , and the other of  $R_3$  and  $R_4$  is selected from OH and  $OCH_3$ ;

provided that at least one of the pairs  $R_1$ ,  $R_2$  and  $R_3$ ,  $R_4$  are both OH;


$R_5$  is selected from OH and  $OCH_3$ ; and

— denotes a single or double bond;


or a pharmaceutically acceptable salt or prodrug thereof; said compound or compounds

being administered either alone or in association with one or more pharmaceutically acceptable carriers, diluents, adjuvants and/or excipients.

15. A method for the treatment, prophylaxis, amelioration, defence against, and/or prevention of cancer in a patient in need of said treatment, prophylaxis, amelioration, defence against, and/or prevention, comprising administering to said patient a therapeutically effective amount of one or more compounds of formula I or formula II




(I),



(II)

in which

A is selected from the group consisting of



, and

20 one of  $R_1$  and  $R_2$  is selected from H, OH and  $OCH_3$ , and the other of  $R_1$  and  $R_2$  is selected from OH and  $OCH_3$ ;

one of  $R_3$  and  $R_4$  is selected from H, OH and  $OCH_3$ , and the other of  $R_3$  and  $R_4$  is selected from OH and  $OCH_3$ ;

provided that at least one of the pairs  $R_1$ ,  $R_2$  and  $R_3$ ,  $R_4$  are both OH;

29.08.00

40

$R_5$  is selected from OH and  $OCH_3$ ; and

— denotes a single or double bond;

or a pharmaceutically acceptable salt or prodrug thereof; said compound or compounds being administered either alone or in association with one or more pharmaceutically acceptable carriers, diluents, adjuvants and/or excipients.

*Suff A2*  
16. A method according to claim 13 or 14 wherein said hormone dependent condition is selected from the group consisting of hormone dependent cancers, hormone dependent cardiovascular disorders and hormone dependent menopausal disorders.

17. The use of one or more compounds according to claim 1 for the manufacture of a medicament for the treatment, amelioration, defence against, prophylaxis and/or prevention of one or more conditions selected from the group consisting of menopausal syndrome; osteoporosis; rheumatic diseases; atherosclerosis; premenstrual syndrome; coronary artery spasm; vascular diseases; Buergers Disease; migraine headaches; hypertension; benign prostatic hypertrophy; cancer; Alzheimers disease; inflammatory diseases; baldness; psoriasis; acne; and diseases associated with oxidant stress.

18. Use of one or more compounds according to claim 1 for the treatment, amelioration, defence against, prophylaxis and/or prevention of one or more conditions selected from the group consisting of menopausal syndrome; osteoporosis; rheumatic diseases; atherosclerosis; premenstrual syndrome; coronary artery spasm; vascular diseases; Buergers Disease; migraine headaches; hypertension; benign prostatic hypertrophy; cancer; Alzheimers disease; inflammatory diseases; baldness; psoriasis; acne; and diseases associated with oxidant stress.

19. A microbial culture or a food or drink composition containing at least one microbial strain which microbial strain is capable of producing one or more compounds according to claim 1 from daidzein and/or glycitein.

20. A method for the treatment, prophylaxis, amelioration, defence against, and/or prevention of a hormone-dependent condition in a patient in need of said treatment, prophylaxis, amelioration, defence against, and/or prevention, comprising administering to a subject a therapeutically effective amount of 6,7,4'-trihydroxyisoflavone, or a pharmaceutically acceptable salt or prodrug thereof, either alone or in association with one or more pharmaceutically acceptable carriers, diluents, adjuvants and/or excipients.

21. The use of 6,7,4'-trihydroxyisoflavone for the manufacture of a medicament for the treatment, prophylaxis, amelioration, defence against, and/or prevention of one or more conditions selected from the group consisting of menopausal syndrome; osteoporosis; rheumatic diseases; atherosclerosis; premenstrual syndrome; coronary artery

29.08.00

41

spasm; vascular diseases; Buergers' Disease; migraine headaches; hypertension; benign prostatic hypertrophy; ~~cancer~~; Alzheimers disease; inflammatory diseases; baldness; psoriasis; acne; and diseases associated with oxidant stress.

22. The use of 6,7,4'-trihydroxyisoflavone for the manufacture of a medicament for the treatment, prophylaxis, amelioration, defence against, and/or prevention of a hormone-dependent condition.

add AB  
add AH